Connect with us

Hi, what are you looking for?

War Against Corona

WHO recommends two new drugs to treat Covid-19

The WHO said on Sunday that it has delivered one billionth dose of Covid-19 vaccine via COVAX on January 15 as a shipment of 1.1 million Covid-19 vaccines was dispatched to Rwanda
WHO headquarters in Geneva, Switzerland. Photo: WHO/Christopher Black

Geneva, Jan 14 (MNN) The WHO has recommended two new drugs — baricitinib and sotrovimab — for the treatment of Covid-19.

The extent to which these medicines will save lives depends on how widely available and affordable they will be, the global health body said on Friday.

The first drug, baricitinib, is “strongly recommended for patients with severe or critical Covid-19”.

It is part of a class of drugs called Janus kinase (JAK) inhibitors that suppress the overstimulation of the immune system. The WHO recommends that it is given with corticosteroids.

Baricitinib is an oral drug, used in the treatment of rheumatoid arthritis. It provides an alternative to other arthritis drugs called Interleukin-6 receptor blockers, recommended by WHO in July 2021.
The World Health Organisation also conditionally recommended the use of a monoclonal antibody drug, sotrovimab, for treating mild or moderate Covid-19 in patients at high risk of hospitalisation.

This includes patients who are older, immunocompromised, having underlying conditions like diabetes, hypertension, and obesity, and those unvaccinated.

“Sotrovimab is an alternative to casirivimab-imdevimab, a monoclonal antibody cocktail recommended by WHO in September 2021. Studies are ongoing on the effectiveness of monoclonal antibodies against Omicron but early laboratory studies show that sotrovimab retains its activity.

“The panel of experts developing the guidelines also looked at two other drugs for severe and critical Covid-19: ruxolitinib and tofacitinib. Given their uncertain effects, WHO made a conditional recommendation against their use.”

The latest recommendations, forming the eighth update of WHO’s living guidelines on therapeutics and COVID-19, are based on evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical Covid-19.

The WHO is in discussions with manufacturers to secure global supply capacity and equitable and sustainable access to the newly recommended therapeutics.

The Access to COVID-19 Tools Accelerator (ACT-A) Therapeutics pillar has been engaging with pharmaceutical companies to seek comprehensive access plans for low- and middle-income countries, so that these treatments can be rapidly deployed everywhere, not just in rich countries.

The ACT-A is also looking to expand licensing scope to make the products more affordable.

The two newly recommended drugs – baricitinib and sotrovimab – have been invited for WHO Prequalification, which assesses the quality, efficacy and safety of priority health products to increase access in lower income countries.

Over 15M new Covid cases in week, a record so far; Omicron less severe but dangerous: WHO

11% increase in new coronavirus cases globally, death rate unchanged: WHO

You May Also Like


Cape Town, Jan 23 (MNN) South Africa overcame a late cameo from Deepak Chahar to complete a hat-trick of ODI wins with a four-run...


Chandigarh, Jan 23 (MNN) Ever since the Model Code of Conduct came into force on January 8 with the announcement of Punjab Assembly elections,...


Cape Town, Jan 24 (MNN) India have been fined 40 per cent of their match fee for maintaining a slow over-rate against South Africa...


Melbourne, Jan 26 (MNN) Three years after making her first Grand Slam semi-finals, Danielle Collins returned to the final four at the Australian Open...